Q&A and closing remarks (ID 1800)

Recent advances in metastatic prostate cancer management (ID 1881)

PARPi maintenance: A new paradigm in the management of frontline ovarian cancer (ID 1784)

Welcome, introductions and objectives of the session (ID 1801)

Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion (ID 1882)

What’s new in metastatic pancreatic cancer management? (ID 1785)

The landscape and role of IO-Chemo combination in NSCLC treatment (ID 1802)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC

Lecture Time
12:50 PM - 01:15 PM
Speakers
  • Marina C. Garassino
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Marina C. Garassino

Q&A (ID 1787)

Is immuno-oncology going to replace chemotherapy in advanced HNSCC? (ID 1803)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

EGFR mutant mNSCLC: Single agent or in combination?

Lecture Time
01:15 PM - 01:40 PM
Speakers
  • Fabrice Barlesi
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Fabrice Barlesi

Closing (ID 1788)